Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy
Usman A. Tahir,Paul Kolm,Raymond Y. Kwong,Milind Y. Desai,Sarahfaye F. Dolman,Shuliang Deng,Evan Appelbaum,Patrice Desvigne-Nickens,John P. DiMarco,Gaurav Tiwari,Matthias G. Friedrich,Julissa H. Zelaya-Portillo,Michael Jerosch-Herold,Dong-Yun Kim,Martin S. Maron,Stefan K. Piechnik,Jeanette Schulz-Menger,Hugh Watkins,William S. Weintraub,Stefan Neubauer,Christopher M. Kramer,Petr Jarolim,Robert E. Gerszten,Carolyn Y. Ho,on behalf of the HCMR Investigators
DOI: https://doi.org/10.1161/circheartfailure.124.011707
2024-11-06
Circulation Heart Failure
Abstract:Circulation: Heart Failure, Ahead of Print. BACKGROUND:Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition that can lead to atrial fibrillation, heart failure, and sudden cardiac death in many individuals but mild clinical impact in others. The mechanisms underlying this phenotypic heterogeneity are not well defined. The aim of this study was to use plasma proteomic profiling to help illuminate biomarkers that reflect or inform the heterogeneity observed in HCM.METHODS:The Olink antibody–based proteomic platform was used to measure plasma proteins in patients with genotype positive (sarcomeric) HCM participating in the HCM Registry. We assessed associations between plasma protein levels with clinical features, cardiac magnetic resonance imaging metrics, and the development of atrial fibrillation.RESULTS:We measured 275 proteins in 701 patients with sarcomeric HCM. There were associations between late gadolinium enhancement with proteins reflecting neurohormonal activation (NT-proBNP [N-terminal pro-B-type natriuretic peptide] and ACE2 [angiotensin-converting enzyme 2]). Metrics of left ventricular remodeling had novel associations with proteins involved in vascular development and homeostasis (vascular endothelial growth factor-D and TM [thrombomodulin]). Assessing clinical features, the European Society of Cardiology sudden cardiac death risk score was inversely associated with SCF (stem cell factor). Incident atrial fibrillation was associated with mediators of inflammation and fibrosis (MMP2 [matrix metalloproteinase 2] and SPON1 [spondin 1]).CONCLUSIONS:Proteomic profiling of sarcomeric HCM identified biomarkers associated with adverse imaging and clinical phenotypes. These circulating proteins are part of both established pathways, including neurohormonal activation and fibrosis, and less familiar pathways, including endothelial function and inflammatory proteins less well characterized in HCM. These findings highlight the value of plasma profiling to identify biomarkers of risk and to gain further insights into the pathophysiology of HCM.
cardiac & cardiovascular systems